Risankizumab Bests Ustekinumab in Head-to-Head SEQUENCE Tria

Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.

Related Keywords

France , Laurent Peyrin Biroulet , Roopal Thakkar , Drug Administration , Johnson , Development In Regulatory Affairs , University Hospital Of Nancy , Image Analysis Group Laurent Peyrin Biroulet , News Center , Infinity Institute , Image Analysis Group , University Hospital , Simple Endoscopy Score , Regulatory Affairs , Met All Primary , Secondary Endpoints Versus Stelara , Head To Study , Only Specific , Treat Moderately , Severely Active Crohn , Adults With Moderately , Comparing Intravenous , Assess Change , Disease Activity Index , Adult Participants With Moderate , Severe Crohn , Crohn Disease , Crohn X27s Disease , Cd , Risankizumab , Bustekinumab , Phase 3 , Clinical , Trial , Sequence , Anti Tnf ,